Apotheek Rechtstro
ActiveApotheek Rechtstro has been active since 1996 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €223k and a net result of €91k. Equity remains stable across the filed fiscal years (±0.7% per year). Its solvency ranks better than 29% of 10289 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).
Checked score
Score 2025
65
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability78▼-6
Solvency44▼-56
Growth58=
Track record100
Bankruptcy probability, 12 months
0.5%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €14k at 30 days acceptable
Liquidity tight (current ratio 1.38 against 4.09 in 2024; short-term debt: 58.9% and cash: 21.6% of total assets), and 80.9% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
19.1%
Return on assets
7.8%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-07-2026, 4 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
4 d early
2024
22 d early
2023
20 d early
2022
18 d early
2021
11 d early
2020
19 d late
2019
3 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
19-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€223k▼ 63.4%
2024 · €610k
2018: €638k
2020: €416k
2021: €455k
2022: €480k
2023: €548k
2024: €610k
2018 → 2025
Total assets
€1.17M▲ 56.4%
2024 · €746k
2018: €877k
2020: €772k
2021: €692k
2022: €634k
2023: €704k
2024: €746k
2018 → 2025
Net result
€91k▼ 0.8%
2024 · €92k
2018: €31k
2020: €14k
2021: €39k
2022: €65k
2023: €69k
2024: €92k
2018 → 2025
Working capital
€258k▼ 38.3%
2024 · €418k
2018: €360k
2020: €195k
2021: €226k
2022: €273k
2023: €350k
2024: €418k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€455k-€480k▲ 5.5%€548k▲ 14.3%€610k▲ 11.2%€223k▼ 63.4%
Operating result€62k-€91k▲ 47.6%€95k▲ 3.8%€125k▲ 31.6%€108k▼ 13.7%
Net result€39k-€65k▲ 68.7%€69k▲ 5.6%€92k▲ 33.4%€91k▼ 0.8%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 14% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.17M
Fixed assets
€221k▲ 14.9%
Current assets
€946k▲ 70.8%
Equity and liabilities €1.17M
Equity
€223k▼ 63.4%
Debt
€943k▲ 596%
The debt ratio rises from 18.2% to 80.9%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€138k▼
2024 · €154k
Cash flow
€121k▲
2024 · €121k
Solvency
19.1%▼
2024 · 81.8%
Current ratio
1.38▼
2024 · 4.09
Quick ratio
1.05▼
2024 · 2.71
Debt / equity
4.23▲
2024 · 0.22
ROE
40.8%▲
2024 · 15.0%
ROA
7.8%▼
2024 · 12.3%
Interest coverage
10.10▼
2024 · 32.19
Debt
€943k▲
2024 · €136k
Debt ≤ 1 year
€687k▲
2024 · €135k
Debt > 1 year
€255k
Income taxes
€3k▼
2024 · €29k
Staff costs
€124k▲
2024 · €82k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€746k€1.17M▲
Fixed assets21/28€192k€221k▲
Tangible fixed assets22/27€192k€221k▲
Land and buildings22€144k€142k▼
Plant, machinery and equipment23€30k€44k▲
Furniture and vehicles24€18k€35k▲
Current assets29/58€554k€946k▲
Stocks and contracts in progress3€187k€222k▲
Stocks30/36€187k€222k▲
Amounts receivable within one year40/41€148k€464k▲
Trade receivables40€145k€160k▲
Other amounts receivable41€3k€303k▲
Cash at bank and in hand54/58€209k€252k▲
Deferred charges and accrued income490/1€10k€9k▼
Equity and liabilities
Total equity and liabilities10/49€746k€1.17M▲
Equity10/15€610k€223k▼
Contributions10/11€19k€19k=
Reserves13€592k€204k▼
Tax-exempt reserves132€54k€54k=
Distributable reserves133€538k€151k▼
Profit (loss) carried forward14€0€0=
Amounts payable17/49€136k€943k▲
Amounts payable after more than one year17-€255k
Financial debts170/4-€255k
Amounts payable within one year42/48€135k€687k▲
Current portion of amounts payable after more than one year42-€35k
Trade debts44€109k€148k▲
Suppliers440/4€109k€148k▲
Taxes, remuneration and social security45€22k€26k▲
Taxes450/3€11k€7k▼
Remuneration and social security454/9€11k€19k▲
Other amounts payable47/48€4k€478k▲
Accrued charges and deferred income492/3€304€743▲
Income statement
Code20242025
Non-recurring operating income76A-€27k
Remuneration, social security and pensions62€82k€124k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€29k€30k▲
Other operating charges640/8€3k€3k▲
Non-recurring operating charges66A€138€0▼
Gross operating margin9900€239k€265k▲
Operating profit (loss)9901€125k€108k▼
Financial income75/76B€429€300▼
Recurring financial income75€429€300▼
Financial charges65/66B€5k€14k▲
Recurring financial charges65€5k€14k▲
Profit (loss) for the period before taxes9903€120k€94k▼
Income taxes67/77€29k€3k▼
Profit (loss) for the period9904€92k€91k▼
Profit (loss) for the period to be appropriated9905€92k€91k▼
Appropriation of the result
Profit (loss) to be appropriated9906€92k€91k▼
Transfer from equity791/2€30k€400k▲
Transfer to equity691/2€92k€13k▼
To other reserves6921€92k€13k▼
Profit to be distributed694/7€30k€478k▲
Return on contributions (dividend)694€30k€400k▲
Directors or managers695-€78k
Social balance
Average headcount (FTE)90872.82.8=
The notes to these accounts (21 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
27-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
09-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Highest result since 2018net €92k ▲33.4%
Operating result €125k, net result €92k, both a record.
11-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
31-12
Financial
Equity above €500kEq €548k ▲14.3%
5 profitable years in a row build equity to €548k.
13-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
20-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
19-08
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 19 days late
2020
31-12
Financial
Weakest financial yearnet €14k ▼53%
Net result drops to €14k, the lowest in the series; recovery starts the following year.
28-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
13-08
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema · 13 days late
2018
31-08
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema · 31 days late
2017
08-06
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
no sitting director, no change since 2025
We have established no sitting directors for this company. We derive directors from published Gazette acts; while there are none, or none read, nothing appears here. That does not mean the company has none: the CBE keeps its own list of function holders, which we do not read.
02-04-2025
Christel Van Grootel: Resigned as Director
02-04-2025
Karel Vercruysse: Resigned as Director
Location & real-estate footprint
Registered office, Lochristi · 1 establishment unit since 1997
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rechtstro 299185 LochristiGround area
1,224 m²
Building footprint
303 m²
Volume, LiDAR
1,743 m³
Parcel 44472B2047/00S000, Flanders · tallest building 8.8 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
Apotheek Rechtstro
since 19972.080.313.666
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44472B2047/00S000 | Flanders | 1,224 m² | 1 · 303 m² | 8.8 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2024 · 1 entry · 45 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2024 | 1 | 0 EUR | 45 EUR |
Schemes
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
Recognitions · licences · registrations
Food safety, FASFC
1 siteLochristi2.080.313.666
Similar companies · same sector, comparable size
Pharmacie Henri Ledoux
BE 0422.129.449
Fontaine-l'Evêque · Eq €223k
R&B FARMA
BE 0809.126.191
Antwerpen · Eq €223k
PHARMACIE CORNEZ
BE 0434.096.180
Mons · Eq €223k
APOTHEEK BROOTHAERTS
BE 0784.856.593
Willebroek · Eq €223k
DISTEPHAR
BE 0885.857.745
Zedelgem · Eq €223k
Of 5,223 companies in sector 47730 we hold annual accounts for 3,862. 3,548 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded13-09-1996
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
52310
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
24422
47740Retail trade
47741Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses
52320
71209Other technical testing and analysis
74302
Sources
Crossroads Bank for EnterprisesNational Bank · 29 filingsAddress and cadastre registers
Data from official sources, last processed on 18-09-2026. Scores and ratios are computed by Checked and are not a credit decision.